Infezol-100 solution for infusions 500 ml. №10

Description

Infezol-100 500 ml Storage:

active substances: 1 liter of solution for infusion contains: L-isoleucine 5.85 g; L-leucine 6.24 g; lysine acetate 10.02 g; L-methionine 4.68 g; acetylcysteine ​​0.673 g; L-phenylalanine 5.4 g; acetyltyrosine 2 g; L-threonine 5 g; L-tryptophan 2 g; L-valine 5 g; L-arginine 9.66 g; ornithine hydrochloride 2.42 g; L-histidine 3.3 g; L-alanine 15.5 g; L-aspartic acid 1.91 g; L-glutamic acid 5 g; glycine 7.55 g; L-proline 7.5 g; L-serine 4.3 g; L-malic acid 3 g; sodium acetate · 3 H2O 3,456 g; sodium chloride 0.625 g; sodium hydroxide 1,324 g; potassium chloride 3.355 g; calcium chloride · 2 H2O 0.735 g; magnesium chloride · 6 H2O 1,017 g;

Excipient:

water for injections.

Infezol-100 250 ml Dosage form.

Solution for infusion.

Main physical and chemical properties: a clear liquid from almost colorless to pale yellow, with virtually no particles.

1 liter of solution for infusion contains: amino acids – 100 g; total nitrogen – 15.6 g; total energy – 1700 kJ / 400 kcal. pH 5.9-6.3. Theoretical osmolarity – 1145 mOsm. Titrated acidity – max. 25 mmol to pH 7.4.

Infezol-100 500 ml Pharmacotherapeutic group.

Means for parenteral nutrition. ATX code B05B A10.

Pharmacological properties.

Pharmacodynamics.

Amino acids are components necessary for protein synthesis. Amino acid-containing solutions are used for parenteral therapy with energy carriers, electrolytes, and fluids to maintain or improve the condition of the body or, under known conditions, to minimize weight loss. In pathological conditions, in the absence of exogenous administration of amino acids, there are significant and typical changes in the set of amino acids in blood plasma, and this applies to both the absolute concentration of individual amino acids and their percentage in blood plasma.

Pharmacokinetics.

Amino acids are fully used for protein synthesis. Excess amino acids that are not required for the synthesis of proteins and other biomolecules cannot be accumulated as a reserve like fatty acids and glucose. Only 5% of amino acids can be excreted unchanged. The cleavage of amino acids occurs by deamination of the α-amino group, which is converted into urea, which, in turn, is excreted by the kidneys. The remaining carbohydrate skeleton is included in the citric acid cycle, where it is converted into acetyl-Co-A, acetone acetyl-Co-A, pyruvate or an intermediate.

Clinical characteristics.

Indication.

Parenteral nutrition with concomitant use of infusion solutions containing carbohydrates, when oral or enteral nutrition is impossible, insufficient or contraindicated.

Contraindication.

Hypersensitivity to any amino acid that is part of the drug;

congenital disorder of amino acid metabolism;

unstable life-threatening blood circulation (shock);

insufficient oxygen supply to cells;

metabolic acidosis;

progressive liver pathology;

severe renal failure, in which the patient is not treated by hemodialysis or hemofiltration;

pathologically high level in the blood plasma of any electrolyte that is part of the drug;

decompensated heart failure;

acute pulmonary edema;

state of hyperhydration;

phenylketonuria.

Special security measures.

Use only clear solutions in undamaged vials. The bottle should be used immediately after opening! Never store the vial open for future use! Amino acid-containing solutions should not be mixed with other drugs due to the increased risk of microbial contamination and incompatibility.